• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
CONCLUSIONS: High-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in Japanese patients with stable coronary artery disease. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01042730. PMID: 29735587 [PubMed - in process]
Source: Circulation - May 8, 2018 Category: Cardiology Authors: Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, T Tags: Circulation Source Type: research

Rationale and Design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial
Publication date: Available online 8 January 2018 Source:American Heart Journal Author(s): Otavio Berwanger, Pedro G.M. de Barros e Silva, Frederico Toledo Campo Dall Orto, Pedro Beraldo de Andrade, Igor Ribeiro de Castro Bienert, Carlos Eduardo Bosso, José Mangione, Carisi Anne Polanczyk, Amanda Sousa, Renato Kalil, Luciano de Moura Santos, Andrei C. Sposito, Rafael L. Rech, Antonio Carlos Sobral Sousa, Felipe Baldissera, Bruno Ramos Nascimento, Isabella de Andrade Jesuíno, Eliana Vieira Santucci, Lucas Petri Daminani, Ligia N Laranjeira, Juliana A Borges de Oliveira, Roberto R Giraldez, Alexandre Biasi Cavalcanti, Sab...
Source: American Heart Journal - January 9, 2018 Category: Cardiology Source Type: research

Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013
CONCLUSIONSAmong CS and NCP with AMI in Ontario, similar improvements in mortality and receipt of treatments were observed between 1995 and 2013. However, compared with NCP, CS had a higher risk of mortality and heart failure. Cancer 2017. © 2017 American Cancer Society.
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Inna Y. Gong, Andrew T. Yan, Dennis T. Ko, Craig C. Earle, Winson Y. Cheung, Stuart Peacock, Marlous Hall, Chris P. Gale, Kelvin K. W. Chan Tags: Original Article Source Type: research

Clinical Characteristics and Long-Term Outcomes of Rotational Atherectomy 　- J2T Multicenter Registry.
CONCLUSIONS: This study has provided the largest Japanese dataset for long-term follow-up of RA. Although RA in calcified lesions appears feasible with a high rate of procedural success, a high incidence of MACE was observed. PMID: 28931790 [PubMed - as supplied by publisher]
Source: Circulation Journal - September 21, 2017 Category: Cardiology Authors: Okai I, Dohi T, Okazaki S, Jujo K, Nakashima M, Otsuki H, Tanaka K, Arashi H, Okabe R, Nagura F, Nara Y, Tamura H, Kurata T, Kawashima H, Kyono H, Yamaguchi J, Miyauchi K, Kozuma K, Hagiwara N, Daida H Tags: Circ J Source Type: research

Improved outcomes in patients with ST-elevation myocardial infarction during the last 20  years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014
ConclusionGradual implementation of new and established evidence-based treatments in STEMI patients during the last 20  years has been associated with prolonged survival and lower risk of recurrent ischaemic events, although a plateauing is seen since around 2008.
Source: European Heart Journal - August 29, 2017 Category: Cardiology Source Type: research

Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Original Articles
Conclusions— Addition of ezetimibe to statin therapy in patients with a recent acute coronary syndrome leads to reductions in cardiovascular-related hospitalizations and associated costs, with the greatest cost offsets in high-risk patients. These cost reductions may completely offset the cost of the drug once ezetimibe becomes generic, and may lead to cost savings from the perspective of the healthcare system, if treatment with ezetimibe is targeted to high-risk patients. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique Identifier: NCT00202878
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2017 Category: Cardiology Authors: Pokharel, Y., Chinnakondepalli, K., Vilain, K., Wang, K., Mark, D. B., Davies, G., Blazing, M. A., Giugliano, R. P., Braunwald, E., Cannon, C. P., Cohen, D. J., Magnuson, E. A. Tags: Secondary Prevention, Cost-Effectiveness, Health Services Original Articles Source Type: research

Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study.
CONCLUSIONS: Real-world evidence indicates that few high-risk patients initiate therapy with high-intensity statins. More than 50% of patients underwent a rechallenge or switching. Despite high CVD risk profile, approximately 20% of patients permanently discontinued any LLT. Key limitations: Pharmacy claims do not provide information on whether patients who had a pharmacy fill actually took the medication as prescribed. It is unknown whether rechallenge was a simple delay in filling a prescription or an actual rechallenge of their index therapy. Reasons for treatment discontinuations or modifications were unavailable in cl...
Source: Current Medical Research and Opinion - March 10, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Prognostic Analysis for Cardiogenic Shock in Patients with Acute Myocardial Infarction Receiving Percutaneous Coronary Intervention.
Abstract Cardiogenic shock (CS) is uncommon in patients suffering from acute myocardial infarction (AMI). Long-term outcome and adverse predictors for outcomes in AMI patients with CS receiving percutaneous coronary interventions (PCI) are unclear. A total of 482 AMI patients who received PCI were collected, including 53 CS and 429 non-CS. Predictors for AMI patients with CS including recurrent MI, cardiovascular (CV) mortality, all-cause mortality, and repeated-PCI were analyzed. The CS group had a lower central systolic pressure and central diastolic pressure (both P < 0.001). AMI patients with hypertension h...
Source: Biomed Res - March 4, 2017 Category: Research Authors: Lin MJ, Chen CY, Lin HD, Wu HP Tags: Biomed Res Int Source Type: research

Clinical Outcomes in Diabetic Patients Who Underwent Percutaneous Coronary Intervention during the Plain Old Balloon Angioplasty (POBA)-, Bare Metal Stents (BMS)- and Drug-eluting Stents (DES)-eras from 1984 to 2010.
Conclusion The incidence of 3-year cardiovascular events decreased from 1984 to 2010 in patients with diabetes following PCI, despite the higher risk profiles in the DES-era. PMID: 28049984 [PubMed - in process]
Source: Internal Medicine - January 6, 2017 Category: Internal Medicine Tags: Intern Med Source Type: research

Lp(a) and cardiovascular risk: investigating the hidden side of the moon
Conclusions Lipoprotein (a) (Lp[a]) seems to significantly influence the risk of cardiovascular events. The effects of statins and fibrates on Lp(a) are limited and extremely variable. Nicotinic acid was shown effective in reducing Lp(a) but, due to its side effects and serious adverse events during clinical trials, it is no longer considered a possible option for treatment. To date, the treatment of choice for high levels of Lp(a) in high CV risk patients is represented by LDL-Apheresis. Thanks to innovative technologies, new selectively inhibiting LPA drugs are being developed and tested.
Source: Nutrition, Metabolism and Cardiovascular Diseases - July 13, 2016 Category: Nutrition Source Type: research

Cardioembolic Stroke - Postmyocardial Infarction Stroke
Ischemic stroke following acute myocardial infarction (AMI) is a rare but serious complication due to left ventricular thrombus formation and atrial fibrillation. Early revascularization of the culprit coronary lesion is essential. Treatment trends may affect the risk. Conversely, the greater use of antiplatelet agents to reduce the risk of ischemic stroke could increase the risk of hemorrhagic stroke. The risk of stroke after AMI has decreased significantly with more use of percutaneous coronary intervention and antithrombotic therapies in the acute setting, and statins, antihypertensive medications, and dual antiplatelet...
Source: Cardiology Clinics - March 12, 2016 Category: Cardiology Authors: Marius Hornung, Jennifer Franke, Sameer Gafoor, Horst Sievert Source Type: research

Cardioembolic Stroke and Postmyocardial Infarction Stroke
Ischemic stroke following acute myocardial infarction (AMI) is a rare but serious complication due to left ventricular thrombus formation and atrial fibrillation. Early revascularization of the culprit coronary lesion is essential. Treatment trends may affect the risk. Conversely, the greater use of antiplatelet agents to reduce the risk of ischemic stroke could increase the risk of hemorrhagic stroke. The risk of stroke after AMI has decreased significantly with more use of percutaneous coronary intervention and antithrombotic therapies in the acute setting, and statins, antihypertensive medications, and dual antiplatelet...
Source: Cardiology Clinics - March 11, 2016 Category: Cardiology Authors: Marius Hornung, Jennifer Franke, Sameer Gafoor, Horst Sievert Source Type: research

Abstract 112: Adherence and Persistence with Statins in Patients with ASCVD Session Title: Abstract Poster Session I and Reception
Conclusions: While patients remained on their first statin (or ezetimibe) therapy for a substantial period of time, a large proportion of patients eventually discontinue therapy. Overall, adherence was high, indicating that ASCVD patients are compliant with their LLT. Interventions and new treatments to improve lipid lowering therapy seem necessary in patients with ASCVD.
Source: Circulation: Cardiovascular Quality and Outcomes - February 26, 2016 Category: Cardiology Authors: Burke, J. P., Paoli, C. J., McPheeters, J., Gandra, S. R., Simpson, R. J. Tags: Session Title: Abstract Poster Session I and Reception Source Type: research

Carotid artery stenting outcomes in high-risk patients receiving best medical therapy: Results from a single high-volume interventional cardiology practice
Conclusions The study demonstrated acceptable clinical outcome results in patients with high medical comorbidities treated with CAS and intensive medical therapy. Adverse event rate in symptomatic patients did not exceed the guideline recommended range while in asymptomatic patients it was increased.
Source: Cor et Vasa - February 23, 2016 Category: Cardiology Source Type: research

Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2)
Conclusions Our study showed that the composition of Iranian patients with ACS regarding the type of ACS is similar to that in developed European countries and is unlike that in developing countries of the Middle East and Africa. We found that our patients with ACS are treated with high levels of adherence to guideline-recommended in-hospital medications.
Source: BMJ Open - December 15, 2015 Category: Journals (General) Authors: Kassaian, S. E., Masoudkabir, F., Sezavar, H., Mohammadi, M., Pourmoghaddas, A., Kojouri, J., Ghaffari, S., Sanaati, H., Alaeddini, F., Pourmirza, B., Mir, E., on-behalf of the IPACE2 registry investigators Tags: Open access, Cardiovascular medicine, Evidence based practice, Medical management Research Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11